

24741-1529

09 / 890649

**-TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)

INTERNATIONAL APPLICATION NO. PCT/EP00/00831	INTERNATIONAL FILING DATE 02 February 2000 (02.02.00)	PRIORITY DATE CLAIMED 03 February 1999 (03.02.99)
---	--	--

TITLE OF INVENTION METHOD FOR THE ENRICHMENT OR DEPLETION OF TUMOR CELLS FROM A BODY FLUID AND KIT SUITABLE THEREFOR
--

APPLICANT(S) FOR DO/EO/US Michael W. DAHM, Robert C. PHELPS, and Carsten BROCKMEYER
--


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US)
6. A translation of the International Application into English (35 U.S.C. 371 (c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A FIRST preliminary amendment.
 A SECOND or SUBSEQUENT preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information:

Unexecuted Oath and Declaration
Copy of PCT Publication

U.S. APPLICATION NO. If known, see 37 CFR 1.50 09/890649	INTERNATIONAL APPLICATION NO PCT/EP00/00831	ATTORNEY'S DOCKET NUMBER 24741-1529		
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY		
Basic National Fee (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$100.00				
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$860.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 ____ 30 ____ months from the earliest claimed priority date (37 CFR 1.492(e))		\$		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	-20 =		X \$18.00	\$
Independent Claims	-3 =		X \$80.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =		\$860.00		
Applicants claim small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.		\$		
SUBTOTAL =		\$		
Processing fee of \$130.00 for furnishing English translation later the 20 ____ 30 ____ months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$		
TOTAL NATIONAL FEE =		\$		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$		
TOTAL FEES ENCLOSED =		\$860.00		
		Amount to be: refunded	\$	
		charged:	\$	
a. <input checked="" type="checkbox"/> A check in the amount of to cover the above fees is enclosed. b. Please charge my Deposit Account No. in the amount of to the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>08-1641</u> . A duplicate copy of this sheet is enclosed.				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO: Customer ID No. 26633 Patricia D. GRANADOS HELLER EHRLMAN WHITE & MCAULIFFE, LLP 1666 K Street, NW, Suite 300 Washington, DC 20006 Tel: (202) 912-2000 Fax: (202) 912-2020		 SIGNATURE NAME: PATRICIA D. GRANADOS _____ REGISTRATION NUMBER: 33, 683 DATE: AUGUST 3, 2001		



26633

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:
Michael W. DAHM et al.

U.S. National Stage of PCT/EP00/00831 Art Unit: Unassigned

Filed: Concurrently Examiner: Unassigned

For: METHOD FOR THE ENRICHMENT OR DEPLETION OF TUMOR CELLS FROM A BODY FLUID AND KIT THEREFOR

Preliminary Amendment

Director for Patents
Washington, DC 20231

Sir:

Before action is taken by the Examiner in the captioned application, please amend the claims as set forth in the Claim Amendments below.

Claim Amendments

Please cancel claims 1-35 and add the following new claims:

36. (New) A method for separating tumor cells from a body fluid, comprising centrifuging in a centrifugation vessel a cell separation medium overlaid with a body fluid, wherein the cell separation medium has a density in the range from 1.055 to 1.065 g/ml.

37. (New) The method as claimed in claim 36, wherein the cell separation medium has a density in the range from 1.059 to 1.062 g/ml.

38. (New) The method as claimed in claim 36, wherein the cell separation medium has a density of about 1.060 g/ml.

39. (New) The method as claimed in claim 36, wherein centrifuging is carried out at about 500 to 2000 × g for about 10 to 30 minutes.

40. (New) The method as claimed in claim 36, wherein centrifuging is carried out at about 1000 × g for about 20 to 30 minutes.

41. (New) The method as claimed in claim 36, wherein the cell separation medium is selected from the group consisting of Percoll and Ficoll.

42. (New) The method as claimed in claim 36, wherein said body fluid comprises one or more substances which prevent aggregation of platelets onto tumor cells.

43. (New) The method as claimed in claim 36, wherein the body fluid has been treated to remove substances which promote aggregation of platelets onto tumor cells.

44. (New) The method as claimed in claim 36, wherein the body fluid is peripheral blood.

45. (New) The method as claimed in claim 36, wherein the body fluid is peripheral blood mixed with an anticoagulant substance and diluted with a diluting medium.

46. (New) The method as claimed in claim 44, wherein the peripheral blood is venous or arterial blood.

47. (New) The method as claimed in 36, wherein the body fluid is selected from the group consisting of lymph, urine, exudates, transudates, spinal fluid, seminal fluid, saliva, fluids from natural or unnatural body cavities, bone marrow and dispersed body tissue.

48. (New) The method as claimed in claim 36, further comprising cooling a lower portion of the centrifugation vessel after centrifuging and before removing an interphase enriched in tumor cells.

49. (New) The method as claimed in claim 36, wherein the centrifugation vessel is divided into an upper compartment and a lower compartment, and wherein the cell separation medium is introduced into the lower compartment, and the body fluid is introduced in the upper compartment.

50. (New) The method as claimed in claim 49, wherein the upper and lower compartments are divided by a porous barrier, a filter, a sieve or a flap.

51. (New) The method as claimed in claim 50, wherein the porous barrier, the filter, the sieve or the flap have a thickness of 0.5-10 mm.

52. (New) The method as claimed in claim 50, wherein the porous barrier, the filter, the sieve or the flap have a thickness of 1-5 mm.

53. (New) The method as claimed in claim 50, wherein the porous barrier, the filter or the sieve have a pore size of 20-100 μm .

54. (New) The method as claimed in claim 50, wherein the porous barrier, the filter or the sieve have a pore size of 20-30 μm .

55. (New) The method as claimed in any of claim 50, wherein the porous barrier, the filter, the sieve or the flap comprises a hydrophobic material or are coated with a hydrophobic material.

56. (New) The method as claimed in claim 36, wherein the cell separation medium comprises a dye wherein said dye allows the cell separation medium to distinguish from the overlying body fluid by color, and allows localization of an interphase enriched in tumor cells.

57. (New) The method as claimed in claim 36, wherein the body fluid comprises non-tumor cells having telomerase activity and telomerase-positive tumor cells, and wherein said method further comprises forming an interphase enriched in the non-tumor cells having telomerase activity and the telomerase-positive cells and depleted from telomerase-positive non-tumor cells.

58. (New) The method as claimed in claim 36, wherein the body fluid comprises tumor cells and blood stem cells, and said method further comprises a first step wherein an interphase is formed enriched in the tumor cells and the blood stem cells and a second step wherein the blood stem cells or the tumor cells are either enriched or depleted.

59. (New) The method as claimed in claim 58, wherein the cell separation medium has a density in the range from 1.061 to 1.065 g/ml.

60. (New) The method as claimed in claim 58, wherein the cell separation medium has a density about 1.062 g/ml.

61. (New) The method as claimed in claim 58, further comprising separating the tumor cells from the blood stem cells.

62. (New) The method as claimed in claim 58, further comprising separating the tumor cells from the blood stem cells by immunoabsorption.

63. (New) The method as claimed in claim 58, wherein said body fluid is selected from the group consisting of bone marrow and peripheral blood.

64. (New) A kit for the separation of tumor cells from a body fluid, comprising a cell separation medium which has a density in the range from 1.055 to 1.065 g/ml.

65. (New) The kit as claimed in claim 64, further comprising a centrifugation vessel.

66. (New) The kit as claimed in claim 64, wherein the cell separation medium has a density in the range from 1.059 to 1.061 g/ml

67. (New) The kit as claimed in claim 64, wherein the cell separation medium has a density of about 1.060 g/ml.

68. (New) The kit as claimed in claim 64, wherein the cell separation medium has a density in the range from 1.061 to 1.065 g/ml.

69. (New) The kit as claimed in claim 64, wherein the cell separation medium has a density of about 1.062 g/ml.

70. (New) The kit as claimed in claim 64, further comprising a centrifugation vessel wherein the centrifugation vessel is divided into an upper compartment and a lower compartment.

71. (New) The kit as claimed in claim 70, wherein the upper and lower compartments are divided by a porous barrier, a filter, a sieve or a flap.

72. (New) The kit as claimed in claim 71, wherein the porous barrier, the filter, the sieve or the flap has a thickness of 0.5-10 mm.

73. (New) The kit as claimed in claim 71, wherein the porous barrier, the filter, the sieve or the flap has a thickness of about 1-5 mm.

74. (New) The kit as claimed in claim 71, wherein the porous barrier, the filter or the sieve have a pore size of 20-100 μm .

75. (New) The kit as claimed in claim 71, wherein the porous barrier, the filter or the sieve have a pore size of 20-30 μm .

76. (New) The kit as claimed in claim 64, further comprising a centrifugation vessel wherein the cell separation medium is present in a lower compartment of the centrifugation vessel.

77. (New) A centrifugation vessel comprising an upper and lower compartment, wherein the upper and lower compartments are divided by a flap.

78. (New) A centrifugation vessel as claimed in claim 77, wherein the flap is closed in the state when the centrifugation vessel is at rest and is opened during centrifugation.

79. (New) A centrifugation vessel as claimed in claim 78, wherein the flap is open by centrifugal force during centrifugation.

80. (New) The centrifugation vessel as claimed 77, wherein the flap has a higher density than a separation medium introduced into the lower compartment.

81. (New) The centrifugation vessel as claimed 77, wherein the flap has a thickness of 0.5-10 mm.

82. (New) The centrifugation vessel as claimed 77, wherein the flap has a thickness of 1-5 mm.

83. (New) The centrifugation vessel as claimed in claim 77, wherein the flap is rigidly connected to the centrifugation vessel.

84. (New) The centrifugation vessel as claimed in claim 77, wherein the flap forms a base of the upper compartment.

85. (New) The centrifugation vessel as claimed in claim 77, wherein the vessel comprises an insert wherein the flap forms the base of the insert.

86. (New) The centrifugation vessel as claimed in claim 77, wherein the vessel flap comprises an outer edge and the flap opens into the lower compartment can opens from the outer edge.

87. (New) A tumor cell culture obtained by a method as claimed in claim 1.

Remarks

Claims 1-35 have been canceled in favor of new claims 36-87. Accordingly, claims 36-87 will be pending with the entry of this amendment. An action on the merits is now awaited. Should there be any questions, the examiner is invited to contact the undersigned at the local exchange listed below.

Respectfully submitted,

August 3, 2001

Date

Patricia D. Granados
Patricia D. Granados
Reg. No. 33,683

Customer No. 26633



Heller Ehrman White & McAuliffe LLP
1666 K Street, N.W., Suite 300
Washington, DC 20007
(202) 912-2000 (telephone)
(202) 912-2020 (telecopier)

PDG:KJP

12/PRIS

09/890649
JC05 Rec'd PCT/PTO 03 AUG 2001

February 2, 2000

Dr. Michael W. Dahm
Gleimstr. 2

81577 Munich

Method for the enrichment or depletion of tumor cells
from a body fluid and kit suitable therefor

5 The invention relates to a method for the enrichment or depletion of tumor cells from a body fluid and to a kit suitable therefor.

Virtually all solid malignant tumors have the potential
10 to form metastases. The metastasis process comprises the spread of malignant cells as micrometastases, usually via the blood or lymph to remote organs and the development of autonomous secondary tumors. The extent of the filiarization determines the prognosis of an
15 oncosis.

The requirements of tumor prevention or aftercare programs are to diagnose primary tumors or recurrences early, or metastases even before they become clinically
20 manifest. This aim cannot yet be satisfactorily met with the available instrumental techniques. Detection of circulating tumor cells for example in peripheral blood would make it possible to initiate a possibly curative immunomodulating therapy or polychemotherapy
25 at an early date, that is to say even before the appearance of a tumor which is noticed clinically. Quantification of tumor cells in peripheral blood before and after the therapy represents an important control in such cases.

30

Since body fluids generally contain a large number of widely differing cells, it is desirable before quantification of particular cell types, such as tumor

cells, to enrich the latter and, at the same time, to deplete a maximum quantity of unwanted cells in order to facilitate the quantification.

5 In addition, a promising approach to the quantification of tumor cells is to determine the telomerase activity of a body fluid. For example, Kim et al. describe, in Science (1994) 266: 2011, an assay with which telomerase activities in tumor tissues can be
10 determined.

However, in peripheral blood, an elevated telomerase activity is shown not only by tumor cells but also by hematopoietic stem cells and activated lymphocytes.

15 Because of this fact it is necessary before detecting a telomerase activity as marker of disseminated circulating tumor cells in the blood to carry out a separation of the telomerase-active hematopoietic stem cells and lymphocytes from the tumor cells.
20

Besides the quantification of tumor cells in body fluids, however, histological examination thereof under a microscope may also be of interest, for example. In addition, tumor cells isolated under sterile conditions
25 can be cultured in order to establish corresponding cell lines therefrom. Cell lines derived from disseminated circulating tumor cells instead of from solid tumors provide the opportunity of being able to investigate metastatic processes in a differentiated
30 manner. In addition, the cell lines might contribute, for example, to the development of more effective tumor therapeutic agents.

For the enrichment of tumor cells it is possible, for
35 example, for epithelial tumor cells to be labeled with the aid of specific antibodies against epithelial cell-specific antigens such as, for example, EPCAM (epithelial cell adhesion molecule), HEA (human epithelial antigen) and cytokeratin 7/8, and be coupled

to magnetic particles or fluorescent molecules, and then be used for the enrichment by means of a cell separator such as MACS (magnetic cell sorting) or FACS (fluorescence activated cell sorting). However, the
5 methods have the disadvantage that only tumor cells of epithelial origin are detected, but not, for example, melanoma cells. In addition, these methods are complicated and costly.

10 In the 1960s and 1970s, when methods like, for example, FACS or MACS were not yet available, tumor cells were separated from hematopoietic cells on the basis of their different density (J.A. Fleming et al., J. clin. Path. (1967), 20, 145). According to these data, tumor
15 cells have a specific density of 1.040-1.080, whereas erythrocytes and polymorphonuclear leukocytes have a higher density. Lymphocytes by contrast have a specific density in the region of 1.060-1.075 and thus overlap with the specific density of tumor cells. Complete
20 removal of lymphocytes, which likewise have telomerase activity, from tumor cells via differences in their densities therefore ought to be impossible. Thus, the use of a standard solution for isolating lymphocytes, such as, for example, Histoprep® (Sigma) with a density
25 of 1.077 g/ml, also showed that lymphocytes from healthy blood donors with a density of up to 1.077 g/ml have telomerase activity.

Despite extensive research, it has not to date been
30 possible to develop a simple, rapid and low-cost standard method for enriching tumor cells from body fluids, in which non-tumor cells with telomerase activity are also removed.

35 One object of the present invention is thus to provide a method for the enrichment or depletion of tumor cells from a body fluid which does not have the above-mentioned disadvantages and, in particular, is also

able to remove non-tumor cells having telomerase activity from the required tumor cells.

It has now been found, surprisingly, that this object
5 can be achieved by overlaying a cell separation medium
with a density in the range from 1.055 to 1.065 g/ml
with the body fluid containing tumor cells, and
centrifuging. The use of the specific cell separation
medium results in the cells present in the body fluid
10 being fractionated in such a way that the lymphocytes
enriched together with the tumor cells because of their
density have no telomerase activity.

The present invention thus relates to a method for the
15 enrichment or depletion of tumor cells from a body
fluid, in which a cell separation medium is overlaid
with the body fluid and centrifuged, wherein the cell
separation medium has a density in the range from 1.055
to 1.065 g/ml.

20 It is self-evident that the method of the invention can
be employed both for the enrichment and for the
depletion of tumor cells, depending on which fraction
is further processed after the centrifugation. No
25 distinction will therefore be made hereinafter between
these two possible further treatments; on the contrary
mention will be made in general of enrichment with,
however, both possibilities always being included
according to the invention.

30 The enrichment method uses a cell separation medium as
discontinuous gradient which is overlaid with the body
fluid. Centrifugation fractionates the cells according
to their specific cell density, and they can be removed
35 in individual fractions. The specific degree of density
of the cell separation medium allows tumor cells to be
separated almost completely from the corpuscular
portions present in the body fluids, specifically the
cells of the red and white blood system. In addition,

the method allows the separation of telomerase-positive from telomerase-negative hematopoietic cells, and the enriched tumor cells are present after the centrifugation in the same fraction as the telomerase-
5 negative hematopoietic cells, so that subsequent detection of telomerase expression in this fraction can be attributed without doubt to the presence of tumor cells.

10 It is also surprising that a considerable reduction in the contaminating blood cells is achieved by a reduction which is only slight compared with the prior art in the density of the cell separation medium. This leads to a significant reduction in the total number of
15 cells without significant losses of tumor cells occurring, which makes, for example, the screening of microscopic specimens considerably simpler and possible for the first time on the clinical scale.

20 It has been found that a particularly good separation efficiency, in the sense of an enrichment of tumor cells and a simultaneous depletion of unwanted blood cells, is achieved with a cell separation medium having a density in the region of 1.055-1.065 g/ml, preferably
25 of 1.059-1.062 g/ml and particularly preferably of about 1.060 g/ml, in particular 1.060 g/ml ± 0.0005 g/ml.

It has also been found that the separation efficiency
30 of the cell separation medium also depends on the age of the blood after blood sampling, and on the concentration of the anticoagulants added to the blood. It has also been found that with fresh blood, i.e. blood investigated on the same day (= 24 hours) of
35 blood sampling, a particularly good separation efficiency is achieved with a cell separation medium in the particularly preferred region of about 1.060 g/ml ± 0.0005 g/ml.

The centrifugation is advantageously carried out at about 500 to 2 000 × g, preferably at about 1 000 × g for about 10 to 30 minutes, preferably for 20-30 minutes. The temperature during the 5 centrifugation is preferably about 4°C. This has the effect that the catalytic activity of proteases, DNases and RNAses is kept as low as possible.

It is possible in principle to use as cell separation 10 medium any suitable liquid of the required density. The cell separation medium ought not to react with the body fluid or the cells present therein. For example, Ficoll or Percoll or a Percoll- or Ficoll-like medium can advantageously be used, the solutions being in each 15 case adjusted to the required density in accordance with the manufacturer's instructions. For example, the amount of Percoll stock solution with a density of 1.13 g/ml which is to be diluted to prepare 100 ml of a Percoll working solution of the required density (dd) 20 is calculated by the formula:

$$100 \text{ ml} \times (\text{dd} - 0.106 - 0.9) / 0.13$$

10% of the Percoll working solution of the required 25 density always consists of a 10 × physiological solution such as, for example, 10 × PBS (phosphate-buffered saline solution), or of a 1.5M NaCl solution, in order to ensure a physiological osmolarity. The difference between the amount of Percoll stock solution 30 (density 1.13 g/ml) calculated by the above formula with the saline solution and 100 ml is then made up with water.

It is thus possible to prepare a Percoll working 35 solution with a density of 1.060 g/ml for example as follows:

41.54 ml of the Percoll stock solution (density of
1.13 g/ml)
48.46 ml of H₂O
10.00 ml of 1.5M NaCl

5

100.00 ml of Percoll working solution, dd 1.060 g/ml

The density of the cell separation medium is
advantageously adjusted with the aid of a density meter
10 (DMA 4500, Anton Paar, Austria) at the appropriate
working temperature of 4°C.

In the subsequent cell separation, care should be taken
that an ambient or working temperature of 8°C is not
15 exceeded. This would lead to a significant reduction in
the Percoll density (compare figure 1) and to unwanted
loss of cells.

The body fluid from which the tumor cells are to be
20 enriched can be any human or animal body fluid or a
dispersion of cellular tissue. Examples thereof are
blood, in particular peripheral blood such as venous or
arterial blood, lymph, urine, exudates, transudates,
spinal fluid, seminal fluid, saliva, fluids from
25 natural or unnatural body cavities, bone marrow and
dispersed body tissue. The fluids from natural body
cavities may be, for example, serous fluids such as
peritoneal and pleural fluids, and the fluids from
unnatural body cavities may be, for example, fluids
30 from cysts.

Preferred body fluids are blood, bone marrow, lymph,
serous fluids from body cavities, and urine, with
particular preference for blood and urine. Urine is
35 particularly suitable for enriching cells from bladder
tumors.

However, the most preferred body fluid is peripheral
blood, which is advantageously removed in an

anticoagulant substance and is diluted with a diluent before overlaying the cell separation medium. It is possible to employ as anticoagulant substances, for example, EDTA or citrate or heparin or CPD (citrate, phosphate, dextrose) or comparable substances. Venous or arterial blood is suitable as peripheral blood.

The body fluid to be investigated is taken or collected in accordance with conventional standard protocols.

5 Depending on the nature of the body fluid it is then either initially diluted with a diluent, preferably a buffer, or directly and undiluted overlaid on the cell separation medium in a centrifugation vessel. An alternative possibility is for the body fluid to be
10 15 centrifuged beforehand at, for example, 1 000 × g for about 10 minutes and, after resuspension of the cells in a buffer, to be overlaid on the cell separation medium. The buffer which is preferably used is Dulbecco PBS. A particularly suitable centrifugation vessel is a
20 25 centrifugation vessel made of plastic such as, for example, polypropylene, in order to prevent nonspecific adsorption of cells. It should be possible to close the centrifugation vessel.

30 35 In a preferred embodiment of the method, the overlaying is preceded by addition to the body fluid of one or more substances which prevent aggregation of platelets onto tumor cells. These substances may, for example, be added together with the buffer used as diluent. Examples of suitable substances which prevent unwanted aggregation of platelets onto tumor cells are EDTA, citrate and ACD-A (acid citrate dextrose). In addition or instead thereof it is possible to remove substances which promote aggregation of platelets onto tumor cells from the body fluid before the overlaying. Examples thereof are ions such as magnesium and calcium ions.

The cell separation medium, which has a higher density than the body fluid to be investigated, is introduced

into the centrifugation vessel and is then overlaid with the body fluid. Depending on the size of the centrifugation vessel and the volume of the body fluid from which the tumor cells are to be enriched, the cell
5 separation medium can be introduced in a volume of 1-500 ml, for example.

It has proved to be particularly advantageous for the lower quarter of the centrifugation vessel to be
10 briefly cooled intensively after the centrifugation and before removing the interphase enriched in tumor cells, in order to prevent contamination with cells. For example, the erythrocytes and leukocytes present in the cell pellet can be immobilized by cooling the lower
15 quarter of the centrifugation vessel intensely in liquid nitrogen for 5-10 minutes. In the present case, the junction between the cell separation medium and the overlying body fluid is referred to as interphase. The tumor cells are enriched in this interphase and are
20 collected after the centrifugation for example by aspirating off this phase. The intense cooling of the centrifugation vessel prevents mixing of the cells from the different phases, which allows false-positive test results to be precluded.
25

In order to ensure that the operations take place as simply as possible, in a preferred embodiment of the method of the invention it is possible to carry out the centrifugation in a vessel which is divided by a
30 barrier, a filter or a sieve, called porous barrier or barrier hereinafter, into an upper and a lower compartment, the cell separation medium being introduced into the lower compartment, and the body fluid being put in the upper compartment. This prevents
35 mixing of the body fluid to be investigated in the upper compartment with the cell separation medium in the lower compartment before and after the centrifugation step.

The position of the porous barrier in the centrifugation vessel can be chosen so that the liquid level of the cell separation medium comes to rest either exactly below, exactly within or exactly above
5 the porous barrier.

The porous barrier can have, for example, a thickness of 0.5-10 mm, preferably of 1-5 mm. The porous barrier should additionally have a strength which allows it to
10 withstand the centrifugal forces without damage.

Barriers preferably used have a porous nature which allows liquids and the corpuscular constituents of the blood, such as the cells of the red and white blood
15 system, which have a higher density than the introduced cell separation medium, to be able to pass unhindered through the porous barrier during the centrifugation. The result of this is that the cell separation medium is forced during the centrifugation through the porous
20 membrane into the upper compartment, and the tumor cells and platelets, which have a lower density than the introduced cell separation medium, come to rest at a level above the barrier. Porous barriers particularly suitable for this purpose have a pore size of
25 20-100 μm , preferably 20-30 μm .

The porous barrier can consist of any suitable material. Plastic, metal, ceramic or a mixture or special alloy of these materials are suitable, for
30 example. However, it is also possible to employ any other natural or artificial material which is suitable.

In an embodiment of the method of the invention which is likewise preferred, the porous barrier consists of a
35 hydrophobic material or is coated with a hydrophobic material.

As an alternative to the barrier in a centrifugation vessel it is also possible to employ a flap which,

analogous to the barrier, divides the centrifugation vessel into an upper and lower compartment.

This flap has a nature which allows it to be tightly
5 closed before and after the centrifugation and to be open only during the centrifugation due to the centrifugal force. During the centrifugation, with the flap open, the liquids in the lower and upper compartment come together. The result of this is that
10 the cells of the red and white blood system, which have a higher density than the introduced cell separation medium, enter the lower compartment and displace the cell separation medium into the upper compartment. The effect of this is that the tumor cells, which have a
15 lower density than the introduced cell separation medium, come to rest at a level above the flap.

It is possible and preferred to use as flap a material which has a higher density than the cell separation
20 medium used and, at the same time, is so flexible that the flap can, during the centrifugation, open into the cell separation medium introduced into the lower compartment and, after the centrifugation, close again completely and tightly. Plastic or metal or a mixture
25 or special alloy of these materials are suitable, for example. It is, however, also possible to employ any other natural or artificial material which is suitable.

The flap can have, for example, a thickness of
30 0.5-10 mm, preferably about 1-5 mm. The flap should additionally have a strength which allows it to withstand the centrifugal forces without damage.

In an embodiment of the method of the invention which
35 is likewise preferred, the flap consists of a hydrophobic material or is coated with a hydrophobic material.

In a preferred use of the flap, attachment of the flap can take place in various ways: a) in analogy to the barrier rigidly connected to the centrifugation vessel, b) rigidly connected to the centrifugation vessel,
5 where the centrifugation vessel itself can be dismantled into 2 parts, into an upper and into a lower part, and the flap forms the base of the upper part (figure 3), or c) rigidly connected to an insert which can be introduced into the centrifugation vessel, with
10 the flap forming the base of the insert (figure 2).

The use of a flap in a divisible centrifugation vessel or in an insert allows a greater degree of automation and an improved sterile handling and has the advantage
15 compared with the barrier that the cells present in the upper compartment after the centrifugation can be centrifuged directly into another vessel, 1) by placing the upper part of the centrifugation vessel on a new lower part or 2) placing the insert in a new
20 centrifugation vessel.

It has proved to be advantageous for the method of the invention to use flaps which, during the centrifugation, open into the lower compartment not
25 from their center but from their outer edges. The reason for this is that with flaps which open at the center the percentage of cells retained at the edges is undesirably high. The result of this is that these cells cannot be fractionated completely in accordance
30 with their density and thus contaminate the enriched tumor cells in the upper compartment of the centrifugation vessel.

Thus, flaps preferred for the method of the invention
35 are those which open into the lower compartment from their outer edges. It has emerged that this form of flap permit [sic] complete separation of cells according to their density. A corresponding wing flap is shown by way of example in figure 3.

It is possible with the aid of the porous barrier or flap to introduce the body fluid to be investigated into the centrifugation vessel without mixing it with
5 the underlying cell separation medium and thus possibly impairing the enrichment or making it impossible.

After the centrifugation, the tumor cells present in
10 the body fluid are located in the interphase of the upper compartment of the centrifugation vessel. About 80% of the liquid above the interphase can then be cautiously aspirated off and discarded. When blood is used as body fluid for example, this residual liquid is plasma, a plasma/PBS or plasma/buffer mixture
15 containing the plasma proteins.

The remaining supernatant above the barrier or flap, in which the tumor cells are located, can subsequently be collected and, for example, transferred into a fresh
20 centrifugation vessel (preferably made of optionally siliconized plastic and having the same volumetric capacity as the centrifugation vessel used previously). The porous barrier or the closed flap prevents the cells in the upper and the lower compartment becoming
25 mixed on removal of the remaining supernatant.

The upper compartment of the centrifugation vessel is then advantageously washed, for example twice, with a buffer, and the latter is likewise transferred into the
30 fresh centrifugation vessel. Suitable buffers are, for example, Dulbecco's PBS (3.9 mM EDTA, pH 8.0 without calcium and magnesium) or NaCl/10% ACD-A (Guidelines for the collection, processing and storage of human bone marrow and peripheral stem cells for
35 transplantation, prepared by the BCSH Blood Transfusion Task. Transfus. Med. 1994; 4: 165-72) or NaCl/5% ACD-A/1% albumin). It has proved to be particularly advantageous to add proteins such as, for example, 0.1% to 10% BSA (bovine serum albumin) to the buffer,

because nonspecific binding of the cells to be collected to surfaces such as vessel wall, barrier or flap, pipette tips etc. is prevented. After a further centrifugation, for example at 1 000 × g for about 5 10 minutes at a temperature of about 4°C, the collected cells can be, for example, supplied for tumor cell detection methods.

10 Since platelets are also enriched in the collected tumor cell fraction, it may be advantageous for the platelets to be washed twice more in a buffer (for example PBS with 0.1% - 10% BSA) and be centrifuged at about 200 × g and 10 minutes if the collected cells are, for example, to be placed on slides.

15 In order to improve the visibility of the cell ring containing the tumor cells after the centrifugation at the interphase between cell separation medium and body fluid for removal from the centrifugation vessel, it 20 has proved to be advantageous to add a dye to the cell separation medium. It is possible to add, for example, 100 µl of a 1% Trypan blue solution to 100 ml of a Percoll working solution.

25 On use of a centrifugation vessel with porous barrier or flap, however, removal of the remaining supernatant liquid above the interphase is preferably followed by removal not just of the interphase but of all of the liquid remaining above the porous barrier, not because 30 further cells are still present between interphase and porous barrier or flap, but because the removal makes it possible easily to mix the cells present in the cell ring. In order not to lose any cells from the upper compartment, the latter is advantageously washed twice 35 more with a buffer (for example PBS with 0.1-10% BSA).

An alternative possibility on use of an insert or of a divisible centrifugation vessel is to centrifuge the cells located above the flap directly into a new

centrifugation vessel. This takes place by introducing the insert into a new centrifugation vessel (figure 4) or fitting the upper part of the centrifugation vessel onto a new lower part.

5

It is possible with the method of the invention to enrich circulating tumor cells and, in particular, circulating tumor cells from solid tumors, i.e. non-hematological tumors, or hematological tumor cells, 10 i.e. tumor cells of the red and white blood system.

It is possible with the tumor cell enrichment method of the invention for tumor cells to be separated, because of their different density, almost completely from the 15 corpuscular constituents of body fluids such as, for example, the cells of the red and white blood system, and be concentrated and, for example, supplied for one of the known tumor cell detection methods.

20 The methods for detecting tumor cells encompass the entire range of current diagnostic methods. Examples thereof are microscopic, immunocytological/immuno-cytochemical, biochemical and/or molecular biological methods. For example, the tumor cells can be detected 25 after the enrichment as whole cells or as cell constituents directly or after cell culture and expansion of the tumor cells by morphological, immunocytological/immunocytochemical, biochemical and/or molecular biological methods. These methods make 30 it possible to detect a whole cell or the specific activity of a cell or to detect specific constituents of a whole cell. Examples of constituents of a whole cell are, inter alia, proteins and glycoproteins of the membrane, of the cytoplasm or of the cell nucleus, and 35 the chromosomes, specific sections of chromosomes and even nucleic acid sequences such as DNA, RNA and cDNA.

Examples of direct cell detection methods are, inter alia, all types of microscopy including staining of

SEARCHED
INDEXED
COPIED
FILED

cells or cell constituents. Examples of direct staining are Trypan blue staining or staining by specific antibodies which are directed against specific constituents of the cell such as the cell membrane, the 5 cytoplasm or the cell nucleus, and onto which labeling signals such as, for example, fluorescent dyes are coupled. Detection methods are, inter alia, flow cytometry or FACS (fluorescence activated cell sorting), ELISA and Western blotting. Further methods 10 for detecting cell constituents are, inter alia, methods for detecting nucleic acids with the aid of labeled probes, for example FISH, in situ hybridization, Northern, Southwestern and Southern blotting or differential display, and, inter alia, the 15 methods for amplifying nucleic acids, inter alia PCR, RT-PCR, in situ RT-PCR and NASBA.

It is advantageous furthermore to employ methods which make a specific binding of an antibody to a protein or 20 of an oligonucleotide to a nucleic acid (DNA, RNA or cDNA) visible through amplification of the signal. One example thereof is the use of specific dendrimers (Polyprobe) (cf. US patent 5,487,973 and Nilsen, T.W., Grayzel, J. and Prensky, W. (1997) J. theor. Biol. 187: 25 273-284). Dendrimers are highly branched structures which preferably consist of nucleic acids and are derived from the sequential hybridization of monomeric structures. A monomer is a heterodimer which consists of two single-stranded nucleic acids which form a 30 double-stranded waist and four single-stranded arms. A dendrimer is made up by sequential binding of such monomers in a plurality of binding planes: the first binding plane consists of four monomers with twelve single-stranded arms. The second plane consists of 35 twelve monomers with 36 single-stranded arms. The sixth plane consists of 972 monomers with 2916 free single-stranded arms. On one of these single-stranded arms it is possible to couple on the one hand specific antibodies or specific probes such as nucleic acids. On

the other single-stranded arm it is possible on the other hand to couple specific labeling signals such as, for example, fluorescent dyes, or radioactive substances. The use of the dendrimers for detecting
5 rare DNA or RNA can take place either directly or indirectly after amplification by, for example, PCR, RT-PCR or NASBA.

10 The subsequent detection methods can be employed in the following areas:

The detection of the tumor cells can be employed directly as tumor marker.

15 In staging investigations, the number of detected circulating tumor cells can be correlated with the clinical picture, and an individual tumor staging can be established. After removal of the primary tumor, the patient can be subjected to regular checks for
20 recurrence and be immediately treated if there is a positive finding. Further possible applications are the detection of residual tumor cells in the bone marrow of patients who have to undergo high-dose radiotherapy or of circulating tumor cells within the framework of ex
25 vivo and in vivo gene therapy approaches.

30 The obtaining of circulating tumor cells makes it possible for therapies to be examined for their efficacy and, where appropriate, modified. This is possible in particular since, after obtaining tumor cells, directly or after culturing and expansion, the individual resistance status of the tumor cells in relation to a cytostatic can be checked and alternative products can be tested. An additional possibility is to
35 test novel therapeutic agents on the tumor cells obtained.

The method is ascribed a particular value within the framework of tumor prevention investigations since

longer survival rates are to be expected with considerably earlier diagnosis and immediate therapy. Further applications are in the production of tumor vaccines and gene therapy.

5

The present invention thus also relates to a method for detecting tumor cells in a body fluid, in which the tumor cells are enriched from the body fluid as described above and, preferably at the same time, 10 unwanted cells are depleted.

In immunocytological/immunocytochemical diagnosis, for example, circulating tumor cells are detected in blood and bone marrow by specific antibodies. For this purpose, about $1-2 \times 10^6$ mononuclear cells (MNC) are put by means of a centrifuge on a slide, stained and evaluated microscopically (Zhong et al. Tumordiagn. u. Ther. (1999) 20: 39). A blood sample contains between [sic] $1-3 \times 10^6$ MNC/ml. Based on an average amount of 20 2×10^6 MNC/ml, 20 ml of blood contain about 40×10^6 MNC, which would have to be investigated on 20-40 slides. Our investigations show that about 1×10^5 cells can be enriched from 20 ml of blood using the method of the invention. This means that evaluation of 25 the tumor cell fraction obtained from up to 200 ml of blood or bone marrow can take place on one specimen.

This example makes it clear that the method of the invention has crucial importance especially in relation 30 to the following factors: 1. economy: saving of time and reagents, 2. quality of the results: for example through the increase in the signal/noise ratio, 3. opening of previously impossible cytobiological or molecular biological investigations on circulating 35 tumor cells: for example single-cell PCR, FISH and gene array scanner analyses and 4. automation and miniaturization of the detection methods: for example HTS (high throughput [sic] systems) and nanotechnology.

Since the probability of obtaining a positive finding within the framework of manifest micrometastasis is significantly improved, the method of the invention additionally has crucial advantages in relation to a
5 standardization of the detection of tumor cells both in bone marrow and in peripheral blood, as required, for example, by the ISHAGE (International Society for Hematotherapy and Graft Engineering [sic]) Working Group for Standardization of Tumor Cell Detection in
10 Borgen et al. in Cytotherapy (1999) 1: 377.

As mentioned, it is possible to automate single steps or a plurality of single steps within the enrichment method of the invention or the entire method itself.
15 All technical methods in which the necessary manipulation can be carried out automatically by robots or specifically designed machines under standardized conditions are suitable for automating the method. Also suitable are systems in which the individual reaction
20 steps can be carried out in minimal volumes. Examples thereof are high throughput systems (HTS) and nanotechnology systems.

For example, the use of microtiter plates permits a
25 greater degree of automation. For the purposes of the enrichment method of the invention it is possible, for example, for the entire range of current diagnostic methods such as, for example, microscopic, immuno-cytological/immunocytochemical, biochemical and/or
30 molecular biological methods to be carried out at the microtiter plate level. Microtiter plates permit the same manipulations for the skilled worker, with the difference that a plurality of samples can be processed simultaneously under standardized conditions and in
35 faster periods.

For the purpose of automating the method of the invention, for example, for the immuno-cytological/immunocytochemical detection it is possible

for different blood or bone marrow samples, after fractionation has taken place, to be processed separately to a cytospin preparation or, alternatively, be centrifuged directly on microtiter plates. A 5 cytospin preparation has a basic area of about 240 mm² onto which 1 × 10⁶ cells are centrifuged. Suitable microtiter plates are, for example, 12-chamber, 24-chamber or 48-chamber plates with a chamber area of in each case respectively about 350 mm², 190 mm² and 10 110 mm².

12-chamber or 24-chamber plates are preferably used, and 24-chamber plates are particularly preferably used, for the immunocytological/immunocytochemical diagnosis. 15 It is further preferred to use microtiter plates in which the chambers can be employed as strips in a frame, for example 3 strips of 4 chambers/12-chamber, 4 strips of 6 chambers/24-chamber and 6 strips of 8 chambers/48-chamber plate.

20 Particularly preferred microtiter plates are those which have a glass base instead of a plastic base, because glass is more suitable than plastic for various applications (for example for immobilizing the cells). 25 In analogy to the cytospin preparations, computer-assisted image analysis is possible for evaluation of the preparations in microtiter plates.

In analogy to the methods in the area of 30 immunocytology/immunocytochemistry, it is likewise possible to carry out the molecular biological diagnostic methods on microtiter plates, with the difference that, after fractionation of the cells, considerably smaller volumes are processed and thus it 35 is possible to use microtiter plates up to HTS (high throughput system) microtiter plates or nanotechnology systems, and the manipulations can be carried out by robots or specifically designed machines under standardized conditions in minimal volumes.

Within the framework of automation of the method according to the invention, inserts can be placed on the microtiter plates which permit the possibility of carrying out the fractionation of the cells in smaller volumes, in analogy to a centrifugation vessel, directly on a microtiter plate. An attachment of this type, in which the individual chambers are provided with flaps in analogy to the centrifugation vessels described, is depicted by way of example in figure 5 for improved understanding.

The present invention thus also relates to methods for the semiautomatic or completely automatic detection of tumor cells in a body fluid, in which the tumor cells have been enriched from a body fluid as described above.

In a special application of the method of the invention it is also possible for tumor cells to be isolated from body fluid and cultivated for example for research and therapy purposes. All systems as well as nanotechnology systems are suitable for the culturing. The culturing of tumor cells can be carried out semiautomatically or completely automatically in these systems under optimized conditions in minimal volumes.

The present invention thus also relates to methods for culturing tumor cells which have been obtained by use of the method of the invention.

In a specific application of the method of the invention it is also possible for tumor cells to be depleted for example from the bone marrow or from the peripheral blood, for example if the donor has been treated with growth factors for the purpose of increasing the blood stem cell content.

An enrichment of blood stem cells both from the blood and from the bone marrow is routinely carried out for the purpose of blood stem cell transplantation. These blood stem cells may be the patient's own (autologous) 5 or foreign ones (allogeneic). Autologous and allogeneic blood stem cell transplantation is applied in particular within the framework of high-dose therapy (for example chemotherapy or radiotherapy) of oncoses and for the therapy of disorders of the hematopoietic 10 system and of autoimmune diseases (for example rheumatism). In the case of enrichment of blood stem cells from the bone marrow, the starting material is obtained directly by removing bone marrow, for example from the iliac crest. In the case of enrichment of 15 blood stem cells from the peripheral blood, the concentration of blood stem cells in the blood is first increased by administration of growth factors. Mononuclear cells (MNC) are subsequently obtained by leukapheresis. The mononuclear cells obtained are then 20 subjected to an enrichment method for blood stem cells. This enriched blood cell fraction is then mixed with DMSO and frozen until transplanted.

In the case of autologous blood stem cell 25 transplantation, the risk of transplanting contaminating tumor cells is particularly high and endangers the success of the therapy. It is therefore desirable before the transplantation to examine the MNC fraction obtained for the presence of tumor cells and 30 to deplete tumor cells which are present.

It has now been found that blood stem cells which carry as surface marker the CD34 antigen are telomerase-positive and have a density of about $1.061 \text{ g/ml} \pm 0.0005 \text{ g/ml}$. This density is so close to the 35 particularly preferred density of $1.060 \text{ g/ml} \pm 0.0005 \text{ g/ml}$ used in the method of the invention for the enrichment of tumor cells that perfect separation of telomerase-positive tumor cells from telomerase-

positive non-tumor cells after a therapeutic mobilization of CD 34+ blood stem cells into the peripheral blood cannot always be ensured completely and reliably.

5

In the case of telomerase detection from the peripheral blood, experiments which have been carried out prove that the cell fraction collected from the interphase, even after a fractionation with a cell separation medium with a density of 1.065 g/ml, was telomerase-negative for all blood samples from the subjects investigated. This means that in the subjects investigated the proportion of CD 34+ cells, or the telomerase activity of the CD 34+ cells, in the peripheral blood was below the detection limit (example 2).

After mobilization of blood stem cells into the peripheral blood it is probable that the collected cell fraction on separation with a density of 1.060 ± 0.0005 g/ml will be telomerase-positive and it is no longer possible to distinguish between telomerase-positive tumor cells and telomerase-positive non-tumor cells. The reason for this is that owing to the stimulation with the growth factors on the one hand the amount of the CD 34+ blood stem cells has increased, and on the other hand the telomerase activity of these cells has increased. There is incomplete depletion of some of these CD 34+ blood stem cells, and thus the telomerase-positive tumor cells present in the interphase are contaminated by telomerase-positive CD 34+ non-tumor cells.

This problem can be solved according to the invention by modifying in this case the method described above in such a way that, in a first step, the CD 34+ blood stem cells are enriched and the unwanted blood cells are depleted to a large extent. Then, in a second step, either the tumor cells are separated from the CD 34+

blood stem cells or the CD 34+ blood stem cells are separated from the tumor cells by immunoabsorption. It has been found that a particularly good separation efficiency, in the sense of depletion of unwanted blood
5 cells with, at the same time, enrichment of CD34+ positive blood stem cells and tumor cells, is achieved by increasing the density of the cell separation medium to a range from 1.061 to 1.065 g/ml and particularly preferably of about 1.062 g/ml, in particular
10 1.062 g/ml ± 0.0005 g/ml.

The second separation step takes place by further enrichment of the required cell populations or depletion of unwanted cells such as, for example, tumor
15 cells in blood stem cell preparations for diagnostic like therapeutic purposes, and is carried out by a subsequent enrichment or depletion method, for example using immunoabsorption methods with specific antibodies.
20

By means of the separation method of the invention it is possible to apply a subsequent depletion method at considerably lower cost after there has already been depletion of a considerable proportion of the unwanted
25 blood cells.

The present invention thus also relates to a method in particular for the detection and for the therapeutic depletion of tumor cells from blood stem cells of bone marrow and peripheral blood, in which the tumor cells and blood stem cells are enriched in a fraction as described above, and the blood stem cells or tumor cells are either enriched or depleted in a second step.
30

35 Since the method of the invention can advantageously be employed within the framework of obtaining therapeutic autologous blood stem cells, it is obvious also to employ this method for obtaining allogeneic blood stem cells.

The method of the invention for enrichment of allogeneic and autologous blood stem cells has the effect that the blood stem cells are enriched
5 considerably better and unwanted blood cells are depleted considerably better than can be carried out with the methods customary to date. This has the particular advantage that the amount of DMSO necessary for cryopreservation of the cells can be reduced
10 considerably. It is thus possible to reduce the complications which are caused by DMSO and arise on transplantation of the blood stem cells.

The present invention thus also relates to a method for
15 the therapeutic enrichment of allogeneic or autologous blood stem cells from bone marrow and peripheral blood, in which in the obtaining of the autologous blood stem cells the tumor cells and blood stem cells are enriched in a fraction as described above, and the blood stem cells or tumor cells are either enriched or depleted in
20 a second step.

A further aspect of the present invention is a kit for the enrichment of tumor cells from a body fluid which
25 is suitable for carrying out the method of the invention. For this purpose, the kit comprises a cell separation medium which has a density in the range from 1.055 to 1.065 g/ml, preferably in the range from 1.057 to 1.063 g/ml, more preferably from 1.059 to 1.061 g/ml
30 and particularly preferably of about 1.060 g/ml, in particular $1.060 \text{ g/ml} \pm 0.0005 \text{ g/ml}$, and, where appropriate, a centrifugation vessel.

A further aspect of the present invention is a kit for
35 the enrichment of blood stem cells from peripheral blood and the bone marrow, which is suitable for carrying out the method of the invention. For this purpose, the kit comprises a cell separation medium which has a density in the range from 1.061 to

00000000000000000000000000000000

1.065 g/ml and preferably of about 1.062 g/ml, in particular 1.062 g/ml \pm 0.0005 g/ml, and, where appropriate, a centrifugation vessel.

5 In order to facilitate routine work with the kit, the centrifugation vessel can have a porous barrier or flap, preferably with a thickness of 1-10 mm, preferably about 1-5 mm, which divides the centrifugation vessel into an upper and a lower
10 compartment. The porous barrier can advantageously have a pore size of 20-100 μm , preferably 20-30 μm , and preferably consists of a hydrophobic material.

15 The flap advantageously opens from its outer edges into the lower compartment and preferably consists of a hydrophobic material. The flap is moreover, in analogy to the barrier, a) rigidly connected to the centrifugation vessel, b) rigidly connected to the centrifugation vessel where the centrifugation vessel
20 itself can be dismantled into 2 parts, into a lower and into an upper part, and the flap forms the base of the upper part, or c) rigidly connected to an insert which can be introduced into the centrifugation vessel, with the flap forming the base of the insert.
25

30 The size of the centrifugation vessel present in the kit should be appropriate for the amount of body fluid from which the tumor cells are to be enriched. For example, the centrifugation vessel can have a volume of 1-500 ml, preferably 1-50 ml and particularly preferably 15-50 ml. The centrifugation vessel can preferably be closed. The centrifugation vessel is preferably sterile or sterilizable and can moreover consist of solid undeformable or else deformable
35 materials (bag) or be a microtiter plate.

In an alternative embodiment, the size of the centrifugation vessel present in the kit should suit the amount of body fluid from which the blood stem

cells are to be enriched. For example, the centrifugation vessel can have a volume of 50-500 ml, preferably 50-250 ml and particularly preferably 50-200 ml. The centrifugation vessel can preferably be 5 closed. The centrifugation vessel is sterile or sterilizable and can moreover consist of solid undeformable or else deformable materials (bag).

10 The cell separation medium in the kit is particularly advantageously already present in the lower compartment of the centrifugation vessel so that the latter can be employed simply and rapidly in routine investigations.

15 In another preferred embodiment, the kit comprises a cell separation medium which is mixed with a dye which makes the interphase between cell separation medium and the interphase more easily visible after the centrifugation.

20 Finally, the invention also advantageously includes centrifugation vessels which can be employed for the enrichment or depletion method of the invention and which have a flap as described above.

25 The method of the invention has the advantage that telomerase-positive non-tumor cells can easily and reliably be separated from the tumor cells to be enriched, so that no false-positive results are obtained in the subsequent detection method due to 30 telomerase-active non-tumor cells. In addition, only a few working steps are necessary for the enrichment and isolation of tumor cells from body tissue, so that this makes it possible to process larger amounts of sample material. The costs for the necessary materials are 35 significantly lower for example compared with the use of specific antibodies and the subsequent separation using suitable apparatuses.

In addition, the investigation of 10 different cell lines derived from tumor tissues, such as melanoma, prostate, breast, lung, liver and colorectal carcinomas, showed that the majority of the cells from 5 all these cell lines were enriched by the method of the invention.

The appended figures show:

10 Figure 1 the result of an investigation of the temperature-dependence of the density of Percoll. The density of the prepared Percoll working solution in a temperature range of about 0°C-8°C is 1.060 ± 0.005 g/ml. At an ambient temperature of more than 8°C, 15 the Percoll working solution starts to expand continuously, and the density originally set to decrease significantly.

Figure 2 shows an example of a centrifugation vessel 20 (1) with a closure (2) and an insert (3) with a flap (4) which is fixed to a transverse strut (5). The transverse strut (5) is firmly connected to the insert (3). The flap (4) forms the base of the insert (3). In the simplest case, the flap is, for example, a disk 25 which is bent by the centrifugation on two sides across the transverse strut (5) into the introduced cell separation medium. The transverse strut (5) also assists complete closure of the flap after the centrifugation. The centrifugation vessel (1) must be 30 closed by the closure (2) during the centrifugation in order to prevent the introduced cell separation medium being forced upward at the gap (s) between centrifugation vessel (1) and insert (3). In addition, the flap (4) can be provided, for example with two additional 35 feet (6) so that the insert (3) can be put down upright on the transverse strut (5) and the feet (6). At the same time, the feet (6) assist opening of the flap because they provide additional weight on the outer edges of the flap (4).

Figure 3 shows an example of a centrifugation vessel (7) which differs from the centrifugation vessel (1) shown in figure 2 consisting of two parts. The upper 5 part (8) can be fitted onto a lower part (9). The flap (4) forms the base, and the closure (2) the lid, of the upper part.

Figure 4 shows an example of the mode of functioning of 10 a flap insert in a centrifugation vessel as used, for example, for separating tumor cells from blood or bone marrow. a) The sample of blood or bone marrow (bk) to be investigated contains, described simply, erythrocytes (rbc), leukocytes (wbc) and tumor cells (tc) and 15 after removal is placed directly in the insert (3) whose base is tightly closed by the flap (4). b) The insert (3) is then introduced, for example, into a 50 ml centrifugation vessel (1) into which an appropriate volume of the cell separation medium (sm) 20 has already been introduced. c) During the centrifugation, owing to the centrifugal force applied, the two sides of the flap (4) are bent across the transverse strut (5) downward into the cell separation medium (sm). This has the effect that the liquids (bk) 25 and (sm) meet, and the cell separation medium (sm) is forced upward through the denser cells (rbc) and (wbc), leading to the tumor cells (tc), which have a low [sic] density than the introduced cell separation medium (sm), coming to rest at a level above the flap (4). 30 d) After the centrifugation, the flap (4) is tightly closed again so that e) the insert (3) with the tumor cells (tc) a small proportion of cell separation medium (sm) and plasma (p) can be transferred f) and g) into a new centrifugation vessel. Renewed centrifugation h) 35 results in the tumor cells (tc) being pelleted i) and they can then j) be further purified and supplied for subsequent investigations.

Figure 5 shows an example of a flap insert for a microtiter plate with a plurality of flaps (4).

Figure 6 shows the result of an RT-PCR analysis of
5 blood from a healthy donor (A) and blood from the same
donor mixed with GFP-transfected cells of the melanoma
cell line T289 (B, C) after enrichment of tumor cells
with a cell separation medium having a density of
1.070 g/ml.

10

Figure 7 shows the result of an RT-PCR analysis of
blood from healthy donors which was mixed with tumor
cells of a prostate carcinoma (A) and breast carcinoma
cell line (B), after enrichment of tumor cells with a
15 cell separation medium having a density of 1.065 g/ml.

Figure 8 shows the recovery rate for GFP-transfected
melanoma cells admixed with blood from different (A, B)
healthy donors, after enrichment with a cell separation
20 medium having a density of 1.065 g/ml.

Figure 9 shows a flow diagram for the RT-PCR.

Figure 10 shows the recovery rate for spiked tumor
25 cells of the breast cancer cell line MDMB 435s in
peripheral blood.

Figure 11 shows the recovery rate for various carcinoma
cell lines.

30

The following examples are intended to explain the
invention in more detail.

Example 1

35

Venous blood (5-20 ml) in a siliconized plastic
centrifugation vessel was mixed with EDTA (3.9 mM final
concentration, pH 8.0) and then with 1 volume of PBS.
The blood/PBS mixture was subsequently put onto 5-10 ml

of Percoll with a density of 1.065 g/ml and centrifuged with slow acceleration and without brake for 30 minutes at 1 000 × g and 4°C. The lower quarter of the centrifugation vessel was then incubated in liquid nitrogen for 5-10 min. This prevented contamination with cells of the pellet while the cells located at the interphase at the junction between the Percoll and the overlying plasma/PBS mixture were being aspirated off. The interphase cells, which were mainly platelets and tumor cells circulating in the blood, were then transferred into a new siliconized plastic centrifugation vessel and centrifuged at 1 000 × g and 4°C for 10 min. For the subsequent RT-PCR investigation, the cell pellet was taken up in a guanidium isothiocyanate buffer, whereby the cells were lysed and could be subjected to RNA isolation.

Example 2

It was shown with the aid of so-called spiking experiments, in which tumor cells of various cell lines were mixed with blood from normal donors, and the tumor cells were then reisolated and investigated in the RT-PCR, that, depending on the cell line used, the telomerase activity of about 1-4 spiked tumor cells/ml of blood can be detected. The RT-PCR was carried out in analogy to the procedure described in example 4.

For this purpose, the cells of the tumor cell lines to be spiked were cultivated to confluence in accordance with the manufacturer's instructions (ATCC, American Tissue Cell Culture). The cells were subsequently trypsinized and washed in medium (RPMI 1640). After removal of a 10 µl aliquot, which was mixed 1:1 with Tryptan blue, the live cells were determined in a counting chamber and the corresponding cell concentration was calculated. The cell suspension was then diluted, and a volume corresponding to a particular number of cells was mixed with the blood

from healthy blood donors. Blood to which no tumor cells were added served as control. The enrichment of the spiked tumor cells was carried out once for comparison with a cell separation medium having a density of 1.070 g/ml and by the method of the invention. The recovery rate was determined by subsequently carrying out microscopic, flow cytometry and RT-PCR analyses.

10 a) Comparative experiment

Figure 6 shows the result of an RT-PCR analysis of 20 ml of blood from a healthy donor (A) and 20 ml of blood from the same donor mixed with GFP-transfected 15 cells of the melanoma cell line T289 (B, C). The blood was layered on Percoll having a density of 1.070 g/ml and centrifuged, and the cells were then analyzed. The catalytic subunit of telomerase (hTRT) is undetectable 20 in normal blood (A), whereas hTRT is detectable with 1 and 2 spiked melanoma cells per ml of blood (B, C). With the Percoll density of 1.070 g/ml used, however, there is still a sufficient number of telomerase-active 25 leukocytes present in the interphase, which makes the RNA component (hTR) also detectable in unspiked blood. The presence of activated and probably therefore also 30 telomerase-active leukocytes in the fraction of isolated cells is also indicated by the fact that CD69, an early activation marker in B and T cells, is detectable in all blood samples (A-C). The tumor marker CEA (carcinoembrionic antigen) is negative both in 35 unspiked and in spiked blood (A-C). GFP (green fluorescent protein), which was used as additional marker for the spiked tumor cells, is not detectable in unspiked blood (A). Since only about 50% of the transfected T289 melanoma cells express GFP, the protein is detectable only in up to 2 spiked tumor cells per ml of blood (B). Actin served as RT-PCR positive control (actin) and in the mixture without RT reaction as negative control (actin ØRT). PCR

amplification of genomic DNA from untransfected T289 cells leads to no amplicons with the specific primer pairs for hTRT, GFP and CD69.

5 b) Experiment according to the invention

Figure 7 shows RT-PCR analyses of blood from healthy donors which was mixed with tumor cells from the prostate carcinoma (A) and breast carcinoma cell line 10 (B), layered onto Percoll having a density of 1.065 g/ml, centrifuged and then analyzed.

The RNA component of telomerase (hTR) is, differing from the use of Percoll with a density of 1.070 g/ml, 15 undetectable in unspiked blood (compare figure 1). It is possible to detect hTR in the samples with 2 spiked prostate carcinoma cells (A) and with 4 spiked breast carcinoma cells (B) per ml of blood (black arrow). These tumor cells differ from the melanoma cell line 20 T289 in that expression of the catalytic subunit (hTR) was not detectable (A) or was detectable only with 10^4 tumor cells (B). Neither the prostate cell-specific marker PSA (prostate specific antigen) nor the epithelial cell-specific marker CK20 (cytokeratin 20) 25 is detectable in the corresponding tumor cells. Actin serves as RT-PCR positive control.

Figure 8 shows the recovery rate for GFP-transfected melanoma cells (T289) with which blood samples from 30 healthy donors were mixed (spiked). The spiked blood samples were then layered onto Percoll having a density of 1.065 g/ml and centrifuged, and the number of reisolated tumor cells (recovery) was determined by microscopy (-●-) and/or flow cytometry (-▲-). Since 35 only about 75% for sample A and 50% for sample B of the GFP-transfected T289 cells were detectable in the flow cytometer, the recovery rates were corrected correspondingly. The recovery rate for spiked tumor cells depends on the particular blood donor (the blood

samples of A) and B) are derived from different donors) and the cell line used, and is inversely proportional to the number of spiked tumor cells. It is possible that a repulsion reaction of the corresponding hematopoietic cells leads to lysis, aggregation and finally to loss of the spiked allogeneic tumor cells. B) additionally shows that the number of actually spiked tumor cells (-■-) is between [sic] 6% - 37% less than the theoretically calculated number of spiked tumor cells (-◆-).

On inclusion of investigations, not shown here, with lung and breast carcinoma cells the average recovery rate with the enrichment method of the invention emerges as $46\% \pm 20\%$ for 4-512 spiked cells ($n = 16$) and $54\% \pm 20\%$ ($n = 15$) for ≤ 50 spiked cells.

This means that the recovery rate in the tumor cell enrichment method of the invention is approximately in the region of magnetic cell separators such as MACS, for which a recovery rate of about 30-58% is stated.

Example 3

Initial clinical investigations on melanoma patients have shown that in 43% of patients with acute metastases and in 16% of patients without manifest acute oncosis (for example after resection of the tumors or after therapy) it was possible to detect telomerase in the disseminated circulating tumor cells in the blood which were enriched with the method of the invention. On the other hand, blood samples from 10 healthy donors which were investigated in parallel were negative.

35

This study on melanoma patients has therefore already shown an unambiguous correlation of the telomerase activity of disseminated circulating tumor cells in the

blood and the metastasis status of the corresponding tumor patients.

Example 4

5

4.1 Isolation of cellular RNA

The isolation of total cellular RNA took place by standard methods [Chomczynski et al. (1987) Anal Biochem 162, 156; Sambrook, J. et al. (1989). Cold Spring Harbor, New York, USA, Cold Spring Harbor Laboratory Press]. Peripheral blood was, as shown in figure 9, immediately after removal transferred into RNA lysis buffer (4M guanidinium isothiocyanate; 0.1M Tris-HCl, pH 7.5; 1% mercaptoethanol) and homogenized. The mixtures were either further processed immediately or stored at -70°C.

20 4.2 Reverse transcription and polymerase chain reaction (RT-PCR)

The RT-PCR was carried out with the GeneAmp® RNA-PCR kit (Perkin Elmer) in accordance with the manufacturer's instructions as shown in figure 9. Aliquots of the isolated total RNA from peripheral blood and cell lines were each previously hydrolyzed with 4U of DNase and 40U of RNase inhibitor (Boehringer, Mannheim) in 36 µl mixtures (in 100 mM Tris-HCl, pH 8.3; 50 mM KCl; 5 mM MgCl₂, 1 mM dNTP mix and 2.5 mM random hexamers) at 37°C for 30 minutes and at 75°C for 10 minutes, and subsequently the DNase was inactivated at 90°C for 10 minutes and then the reaction mixture was immediately put on ice.

35 The two oligonucleotide primers:

5' CTACCGGAAG AGTGTCTGGA GCAAGTTGCA AAGC 3' (hTRT1) and
5' GGCATACCGA CGCACGCCAGT ACGTGTTCTG 3' (hTRT2)

were designed according to the sequence published by Nakamura et al. which codes for the catalytic subunit of human telomerase (Nakamura et al. (1997). Science 277: 955-9) and synthesized with an Applied Biosystem 5 380A synthesizer. The specificity of the hTRT1 and hTRT2 primers was checked by computer-assisted homology analysis on the nucleic acid sequences in the GenBank, EMBL, DDBJ and PDB databases by means of BLASTN 1.4.9 MP [Altschul, S. F. et al. (1990). J. Mol Biol 215: 10 403-410].

Identical amounts of RNA were employed for the RT reaction for each experiment in order to match the amplification amounts. Contamination of the RNA 15 preparations with genomic DNA was precluded by first subjecting each RNA-containing sample hydrolyzed with DNase to the PCR described below, and checking for amplification. The RNA-containing sample with which no amplification product was detectable was employed for 20 the following cDNA synthesis and PCR steps. Oligonucleotide primers for β -actin and TCR were employed as internal standard control. The reverse transcriptase reaction was carried out on 18 μ l of the DNase digest with addition of 50U of MuLV reverse 25 transcriptase and 40U of RNase inhibitor at 42°C for 30 minutes, and the reaction was stopped at 99°C for 5 minutes. In the negative controls 4 μ l of water were added in place of the enzymes.

30 The PCR was carried out as shown in figure 9 on 5 μ l of the cDNA reaction using the following program: (97°C: 15 seconds preheating); (97°C: 15 seconds, 70°C: 30 seconds [minus 0.5°C per cycle], 72°C: 30 seconds) 10 cycles; (94°C: 15 seconds, 65°C: 30 seconds [minus 35 0.5°C per cycle], 72°C: 30 seconds) 20 cycles; (94°C: 15 seconds, 50°C: 30 seconds 72°C: 30 seconds [plus 15 seconds extension per cycle], 10 cycles; (72°C: 7 minutes, final extension).

The amplification products were fractionated by gel electrophoresis on a 1.5% TAE agarose gel, stained with ethidium bromide and visualized under UV light and photodocumented.

5

Example 5

Further spiking experiments as described in example 1 and 2 were carried out with the difference that normal
10 non-siliconized polypropylene centrifugation vessels and Percoll with a density of 1.060 g/ml were used. The intention in these experiments was to determine firstly the degree of depletion of unwanted blood cells and secondly the degree of enrichment of tumor cells.

15

At about 80%-90% confluence, the tumor cell cultures of the breast cancer cell line MDMB 435s were trypsinized, and the cell suspension obtained was transferred into a 15 ml centrifugation vessel and the latter was
20 centrifuged at 500 × g for 5 minutes. The cell pellet was resuspended in 0.5 ml.

25

For staining of the cell nucleus, 100 ml [sic] of the cell suspension (about 10^5 - 10^6 cells) were mixed with 20 ml [sic] of a DAPI solution (intercalating dye; 1 mg of 4',6'-diamidino-2-phenylindole dihydrochloride/ml of dimethyl sulfoxide [DMSO]) in a 1.5 ml centrifugation vessel and incubated at 37°C and at 700 rpm in a Thermomixer (Eppendorf) for 10 minutes. The cells were
30 then pelleted at 500 × g for 5 minutes, resuspended in 1 ml of DPBE (1 ml of 0.1% BSA and 4 mM EDTA in Dulbecco PBS) and again centrifuged at 500 × g for 5 minutes. The washing step was repeated twice. The cells were then adjusted to 2 000 cells/ml of DPBE with
35 the aid of a particle counter (Z2, Beckman Coulter GmbH).

Triplicates of in each case 10, 20, 30, 40, 50, 60 and 70 ml [sic] of the DAPI-positive cell suspension were

pipetted individually into the chambers of a 384 plate. The microtiter plate was then centrifuged at $700 \times g$ for 3 minutes, and the cells were counted with the aid of a fluorescence microscope (Axiovert 25, Zeiss, filter set 02, [extinction 358 nm, emission 460 nm]). A standard line was then formed ($x = \text{ml of DAPI-positive cell suspension}$; $y = \text{number of cells}$). The values of r^2 for the standard line were at least 0.95.

10 In the spiking experiments, an appropriate number of DAPI-positive cells was mixed in triplicates into 20 ml of full blood (Bayerisches Rotes Kreuz, BRK), and the whole blood was put in a 50 ml centrifugation vessel with a porous barrier (pore size 20 - 100 mm [sic])
15 into whose lower compartment 15 ml of Percoll with a density of 1.060 g/ml (at 4°C) and an osmolarity of 280-300 mmol/kg had been introduced. The centrifugation vessel was then centrifuged at 4°C and $1\,000 \times g$ and 4°C [sic] for 30 minutes.

20 After the centrifugation, the interphase cells were transferred with the aid of a 10 ml pipette into a fresh 50 ml centrifugation vessel. The upper compartment of the first centrifugation vessel was
25 cautiously washed twice with 15 ml of DPBE, and the liquid was transferred into the second centrifugation vessel. The centrifugation vessel was then made up to 50 ml with DPBE and centrifuged at $200 \times g$ for 10 minutes. After the centrifugation, the supernatant
30 was decanted off and the cell pellet was resuspended in 5 ml of erythrocyte lysis buffer (155 mM NH₄Cl, 10 mM KHCO₃ and 0.1 mM EDTA pH 7.3) and incubated at room temperature for 5 minutes. After completion of the erythrocyte lysis, the centrifugation vessel was made
35 up to 50 ml of DPBE and again centrifuged at $200 \times g$ for 10 minutes, and the supernatant was decanted off. The cells were then taken up again in 50 - 200 ml of DPBE.

The cell suspension was then divided into two equal aliquots. One aliquot was put into the chamber of a 24 plate and the number of tumor cells in the microtiter plate were determined under the microscope.

5 The total amount of cells in the second aliquot was determined using an automatic hematology analysis system (KX21, Sysmex).

10 The experiments with a Percoll cell separation medium with a density of 1.060 g/ml show 1. a recovery rate of about 73% for the spiked tumor cells (5 - 320 spiked cells, figure 10) and 2. a depletion factor of about 10^3 for leukocytes.

15 **Example 6**

In order to establish whether further tumor cell lines can also be enriched with the method of the invention, the following investigations were carried out: tumor 20 cell lines were cultivated in accordance with the ATCC instructions and harvested as described in example 2 and 5. A particle counter (Beckmann Coulter, Z2) was used to adjust the cell density of the suspension to 2×10^5 cells/ml. 1 ml of this suspension was then 25 cautiously put onto 5 ml of Percoll with a density of 1.060 g/ml in a 15 ml centrifugation vessel and a centrifugation was carried out at $1\ 000 \times g$ and $4^\circ C$ for 30 minutes. Then a 5 ml pipette was used to remove two 30 3 ml fractions and transfer each of them into two separate 15 ml centrifugation vessels. The first fraction contained the interphase cells, and the second fraction contained the remaining cells. The two fractions were centrifuged at $1\ 000 \times g$ for 10 minutes. The supernatant was then decanted off, the cell pellets 35 were each resuspended in 1 ml of DPBE, and the number of cells in the two fractions was determined in a particle counter (Beckmann Coulter, Z2). Figure 11 shows that the investigated cell lines from different organs such as lung (A549, SCLC-H21), prostate (PPC-1)

breast (T47D, MDMB 435s) colon (colo678) and pancreas (CAPAN-2) have a density of < 1.060 g/ml and are more than 90% found in the interphase. This experiment shows that at least all carcinoma cell lines have,
5 irrespective of their origin, a density which allows the possibility of carrying out an enrichment of these cells with the method of the invention.

Example 7

10

The method of the invention was used to carry out at the same time both immunocytological/immunocytochemical investigations and an RT-PCR for detecting telomerase in a number of patients with various manifest
15 carcinomas. After informed consent had been obtained from the patients, up to 30 ml of whole blood were taken from the arm vein and between [sic] 10 to 20 ml were purified using the method of the invention, as described in example 5, and the cell pellet was washed
20 twice in 10 ml of PBS and finally resuspended in 1 ml of PBS and 2 aliquots were formed. The first aliquot was transferred into RNA lysis buffer and stored at -70°C until RNA was extracted and followed by RT-PCR, and the reactions were carried out as described in
25 example 4. The second aliquot was subjected to immuno-cytological stainings. The number of cells applied to a slide corresponded to the equivalent of 10% of the originally purified amount of blood, i.e. with 20 ml of purified whole blood the equivalent of 2 ml of whole
30 blood was concentrated and applied to the slide.

Three stainings were routinely carried out simultaneously:

1. a nuclear staining with an intercalating dye DAPI,
- 35 2. a staining of the epithelial cells with the anti-cytokeratin antibody cocktail (anti-cytokeratin Cam 5.2, B. D.) and 3. A staining of white blood cells with an anti-CD45 antibody in order to preclude nonspecific stainings.

The cell suspension was pipetted onto a slide treated with poly-L-lysine and dried at 4°C overnight. To fix the cells, they were incubated with 100-200 µl of a 2% formaldehyde/DPBS solution at room temperature and then washed 3× with DPBS (with 0.01% NaAz, without EDTA). To permeabilize the cells, a 0.5% Triton X-100/DPBS (with 0.01% NaAz, without EDTA) solution was put on the slide at room temperature for 15 minutes, and then again washed 3× with DPBS (with 0.01% NaAz, without EDTA). To block nonspecific bindings and to stain the cell nuclei, the cells were incubated in 2% BSA/DPBS (with 0.01% NaAz, without EDTA) + 1 µg/ml DAPI at room temperature for 30 minutes and washed 3× with DPBS (with 0.01% NaAz, without EDTA). 80 µl of the monoclonal mouse anti-cytokeratin antibody was put in a 1:500-fold dilution in DPBS (with 0.01% NaAz, without EDTA) on the cells at room temperature for 45 min. After washing three times with DPBS (with 0.01% NaAz, without EDTA), the slide was incubated with 50 µl of a phycoerythrin-conjugated anti-CD45 antibody (goat anti-mouse antibody) at room temperature for 45 min and then washed 3× with DPBS (with 0.01% NaAz, without EDTA). After staining with hematoxylin (50 µl, incubation for 1 min), the slides were washed 3× with H₂O and covered. To check for nonspecific reactions, preparations from healthy blood donors were always included.

Evaluation of these investigations shows that in patients with advanced tumors of the gastrointestinal region, such as, for example, of the esophagus, stomach, colon, rectum and pancreas, and in patients with lung and breast tumors, in 11 of 14 cases cytokeratin-positive CD45-negative epithelial cells were found in the blood. These cells were arranged in the form of clusters and in some cases surrounded by CD45-positive cells, as is typical of cytopsin preparations of circulating tumor cells. These cells are very probably tumor cells because epithelial cells

are not to be expected in this frequency in the blood. The RT-PCR investigations were telomerase-positive in 93% (13/14) of these patients. In patients with locally restricted disease without signs of metastases,
5 circulating epithelial cells were found in the blood in 50% of the cases (3/6). In 67% of these patients (4/6), telomerase was detectable. Investigations on healthy blood donors were epithelial- and telomerase-negative.

10 It was thus possible to show that it is possible to enrich efficiently from the blood not only spiked tumor cells of various cell lines but also circulating tumor cells from patients with various epithelial tumors (carcinomas).

Patent claims

1. A method for the enrichment or depletion of tumor cells from a body fluid, in which a cell separation medium is overlaid with the body fluid and centrifuged, wherein the cell separation medium has a density in the range from 1.055 to 1.065 g/ml.

5

2. The method as claimed in claim 1, wherein the cell separation medium has a density in the range from 1.059 to 1.062 g/ml and preferably of about 1.060 g/ml.

10

3. The method as claimed in claim 1 or 2, wherein the centrifugation is carried out at about 500 to 2 000 × g for about 10 to 30 minutes and preferably at about 1 000 × g for about 20 to 30 minutes.

15

4. The method as claimed in any of the preceding claims, wherein the cell separation medium is Percoll or Ficoll or Percoll- or Ficoll-like.

20

5. The method as claimed in any of the preceding claims, wherein one or more substances which prevent aggregation of platelets onto tumor cells are added to the body fluid before the overlaying, and/or substances which promote aggregation of platelets onto tumor cells are removed from the body fluid before the overlaying.

25

6. The method as claimed in any of the preceding claims, wherein the body fluid is peripheral blood.

30

7. The method as claimed in claim 6, wherein the peripheral blood is removed in an anticoagulant substance and is diluted with a diluting medium before overlaying the cell separation medium.

35

8. The method as claimed in claim 6 or 7, wherein the peripheral blood is venous or arterial blood.

9. The method as claimed in any of claims 1-5, wherein the body fluid is selected from lymph, urine, exudates, transudates, spinal fluid, seminal fluid, saliva, fluids from natural or unnatural body cavities, 5 bone marrow and dispersed body tissue.

10. The method as claimed in any of the preceding claims, wherein the lower quarter of the centrifugation vessel is cooled intensively after the centrifugation 10 and before the interphase enriched in tumor cells, in order to prevent mixing of the cells in the various layers.

11. The method as claimed in any of the preceding 15 claims, wherein the centrifugation is carried out in a vessel which is divided by a porous barrier, a filter, a sieve or a flap into an upper and a lower compartment, the cell separation medium being introduced into the lower compartment, and the body 20 fluid being put in the upper compartment.

12. The method as claimed in claim 11, wherein the porous barrier, the filter, the sieve or the flap have a thickness of 0.5-10 mm, preferably of 1-5 mm.

25 13. The method as claimed in claim 11 or 12, wherein the porous barrier, the filter or the sieve have a pore size of 20-100 μm , preferably 20-30 μm .

30 14. The method as claimed in any of claims 11-13, wherein the porous barrier, the filter, the sieve or the flap consist of a hydrophobic material or are coated with a hydrophobic material.

35 15. The method as claimed in any of the preceding claims, wherein the cell separation medium contains a dye which makes it possible to distinguish the cell separation medium from the overlying body fluid by

color, and thus simplifies the localization of the interphase.

16. The method as claimed in any of the preceding
5 claims, wherein non-tumor cells which have a telomerase
activity are separated from telomerase-positive tumor
cells.

17. A method for detecting tumor cells in a body
10 fluid, in which the tumor cells are enriched by a
method as claimed in any of claims 1-16.

18. A method for culturing tumor cells, in which the
tumor cells are enriched by a method as claimed in any
15 of claims 1-16.

19. A method for the enrichment or depletion of tumor
cells from blood stem cells from bone marrow or
peripheral blood, in which in a first step the tumor
20 cells and blood stem cells are enriched by a method as
claimed in any of claims 1-16, and in a second step the
blood stem cells or the tumor cells are either enriched
or depleted.

25 20. A method for the enrichment of blood stem cells
from bone marrow or peripheral blood, in which in a
first step the blood stem cells and tumor cells are
enriched by a method as claimed in any of claims 1-16,
and in a second step the blood stem cells or the tumor
30 cells are either enriched or depleted.

21. The method as claimed in claim 19 or 20, in which
a cell separation medium with a density in the range
from 1.061 to 1.065 g/ml and preferably of about
35 1.062 g/ml is employed in the first step.

22. The method as claimed in any of claims 19 to 21,
in which the blood stem cells or the tumor cells are

either enriched or depleted by immunoadsorption in the second step.

23. A kit for the enrichment of tumor cells from a
5 body fluid, comprising a cell separation medium which has a density in the range from 1.055 to 1.065 g/ml, and, where appropriate, a centrifugation vessel.

24. The kit as claimed in claim 23, in which the cell
10 separation medium has a density in the range from 1.059 to 1.061 g/ml and preferably of about 1.060 g/ml.

25. A kit for the enrichment of blood stem cells from peripheral blood or bone marrow, comprising a cell
15 separation medium which has a density in the range from 1.061 to 1.065 g/ml, and, where appropriate, a centrifugation vessel.

26. The kit as claimed in claim 25, in which the cell
20 separation medium has a density of about 1.062 g/ml.

27. The kit as claimed in any of claims 23-26, in which the centrifugation vessel has a porous barrier, a filter and a sieve or a flap preferably with a
25 thickness of 0.5-10 mm, preferably about 1-5 mm, which divide the centrifugation vessel into an upper and a lower compartment.

28. The kit as claimed in claim 27, in which the
30 porous barrier, the filter or the sieve have a pore size of 20-100 μm , preferably 20-30 μm .

29. The kit as claimed in claim 27 or 28, in which the cell separation medium is present in the lower
35 compartment of the centrifugation vessel.

30. A centrifugation vessel, which is divided by a flap into compartments one on top of the other.

31. The centrifugation vessel as claimed in claim 30, wherein the flap is closed in the state when the centrifugation vessel is at rest and is opened during the centrifugation by the centrifugal force.

5

32. The centrifugation vessel as claimed in either of claims 30 or 31, wherein the flap has a higher density than the medium introduced into the lower compartment for the centrifugation.

10

33. The centrifugation vessel as claimed in any of claims 30-32, wherein the flap has a thickness of 0.5-10 mm, preferably 1-5 mm.

15

34. The centrifugation vessel as claimed in any of claims 30-33, wherein the flap a) is rigidly connected to the centrifugation vessel, b) is rigidly connected to the centrifugation vessel, where the centrifugation vessel itself can be dismantled into two parts, into a lower and into an upper part, and the flap forms [lacuna] of the upper part, or c) is rigidly connected to an insert which can be introduced into the centrifugation vessel, with the flap forming the base of the insert.

20

35. The centrifugation vessel as claimed in any of claims 30-34, wherein the flap can be opened from its outer edges into the lower compartment.

CROSS-REFS


Abstract

The invention relates to a method for the enrichment or depletion of tumor cells from a body fluid, in which a cell separation medium of specific density is overlaid with the body fluid and is centrifuged. A kit suitable for this method is likewise provided.

09/890649

Michael W. DAHM et al.
U.S. National Phase Application based on
PCT/EP00/00831
1/12
Our reference: 24741-1529


Figure 1



09/890649

Michael W. DAHM et al.
U.S. National Phase Application based on
PCT/EP00/00831
2/12
Our reference: 24741-1529




Figure 2



09/899649

Michael W. DAHM et al.
U.S. National Phase Application based on
PCT/EP00/00831
3/12
Our reference: 24741-1529

Figure 3



09/890649

Michael W. DAHM et al.
U.S. National Phase Application based on
PCT/EP00/00831
4/12
Our reference: 24741-1529

Figure 4





Figure 4
(continuation)



Our reference: 24741-1529

6/12

SEARCHED SERIALIZED INDEXED

Figure 5






Figure 6



Our reference: 24741-1529
8/12


Figure 7



Prostate carcinoma (PC-3)

Breast carcinoma (MD MB-435s)

Figure 8




09/890649

Our reference: 24741-1529
10/12

Figure 9

Whole blood/Ficoll-isolated PBMC




1) PCR conditions:

15"/97°C(15"/97°C,30"/70°C,-0.5°C/cycle,30"/72°C)x10
(15"/94°C,30"/65°C,-0.5°C/cycle,30"/72°C)x20
(15"/94°C,30"/50°C,30"(ext.15"/cycle)/72°C)x10
7'/72°C

Our reference: 24741-1529
11/12

Figure 10




09/890649

Michael W. DAHM et al.
U.S. National Phase Application based on
PCT/EP00/00831

Our reference: 24741-1529 12 / 12

Figure 11



DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

***METHOD FOR THE ENRICHMENT OR DEPLETION OF TUMOR CELLS FROM A BODY FLUID
AND KIT SUITABLE THEREFOR***

the specification of which (check one)

_____ is attached hereto.

_____ was filed on 02 February 2000 as PCT International Application Number PCT/EP00/00831

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of

any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
19904267.5	Germany	03 February 1999	Yes	No

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the following registered attorneys and agents of the law firm of **Heller Ehrman White & McAuliffe** to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith:

PAUL BOOTH	Reg. No. <u>40,244</u>
PATRICIA D. GRANADOS	Reg. No. <u>33,683</u>
JOHN P. ISACSON	Reg. No. <u>33,715</u>
RONALD J. KAMIS	Reg. No. <u>41,104</u>
MARVIN A. MOTSENBOCKER	Reg. No. <u>36,614</u>
COLIN G. SANDERCOCK	Reg. No. <u>31,298</u>
SUSAN E. SHAW MCBEE	Reg. No. <u>39,294</u>

(1)

and I request that all correspondence be directed to:

Patricia D. Granados, Esq.
HELLER EHRMAN WHITE & MCAULIFFE
1666 K Street, NW, Suite 300
Washington, DC 20006
Telephone: (202) 912-2000
Facsimile: (202) 912-2020

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor

1-CL
Michael W. DAHM

Residence

Gleimstrasse 2, D-81677 Munchen, GERMANY

Citizenship

GERMANY

DCI

Post Office Address

Gleimstrasse 2, D-81677 Munchen, GERMANY

Inventor's signature

Michael Dahm

Date

18. 09. 2001

Name of second inventor

2-CL
Robert C. PHELPS

Residence

Dohlenweg 6, D-85757 Karsfeld, GERMANY

Citizenship

GERMANY

DCI

Post Office Address

Dohlenweg 6, D-85757 Karsfeld, GERMANY

Inventor's signature

R. C. Phelps

Date

21/9/2001

Name of Third inventor

Carsten BROCKMEYER

Residence

Thanner Strasse 35a, D-83607 Holzkirchen, GERMANY

Citizenship


GERMANY

DEx

Post Office Address

Thanner Strasse 35a, D-83607 Holzkirchen, GERMANY

Inventor's signature



Date

09/17/01